Dimerix Limited announced that enrolment has been completed for its Phase 2 study of DMX-200 in patients with Diabetic Kidney Disease. The primary end point for the study is the percent reduction in albuminuria (protein in the urine) compared to baseline. Furthermore, an independent statistician has reviewed the variance in baseline data acquired to date and has confirmed that the trial is sufficiently powered to determine a statistically significant result. The Phase 2 study is a double-blind, randomised, placebo-controlled, crossover study designed to evaluate the efficacy and safety of DMX-200 in patients with Diabetic Kidney Disease who are receiving a stable dose of irbesartan. Each participant will receive 12 weeks of the study drug, DMX-200, and 12 weeks placebo, separated by a 6-week washout period. Clinicians at the study sites have reported no safety concerns to date, and Dimerix expects to complete the study in the second quarter of calendar year 2020. The Phase 2 study follows on from a successful Phase 2a study completed in 2017 in patients with a range of chronic kidney diseases. The 2017 study met all primary and secondary endpoints, as well as showing particularly compelling efficacy in the sub-group of patients with diabetic kidney disease.